NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Stock Information for NeuroSense Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroSense Therapeutics Ltd.

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.